Sexual desire and related distress
Phase 3 trials in premenopausal women with diagnosed hypoactive sexual desire disorder (HSDD) found improved desire and reduced related distress compared with placebo.
Read the publication
Physician-led care in the UAE
Peptide care · Pen
PT-141 Pen
Bremelanotide has phase 3 evidence for sexual desire and related distress in a defined group of premenopausal women.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
- Format
- Pen
- Strength
- 10 mg/ml
- Size
- 2 ml
- Route
- Subcutaneous injection
Suitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Where PT-141
has been studied.
The strongest evidence concerns acquired, generalized hypoactive sexual desire disorder in premenopausal women. Early nasal studies in men address a different question.
Studies in men
A smaller intranasal study measured erectile response. It does not establish approval or validation of a compounded nasal treatment for male sexual performance.
Read the publicationSafety & suitability
Is PT-141 right for you?
Nausea, flushing and headache were reported. The approved label includes blood-pressure effects and contraindications in uncontrolled hypertension or known cardiovascular disease.
FDA-approved Vyleesi is indicated for acquired, generalized HSDD in premenopausal women under its label criteria. Approval does not extend to compounded PT-141 preparations or to enhancing sexual performance.
DailyMed: Vyleesi prescribing informationSuitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
PT-141:
what has been studied.
The strongest evidence is for a specific injected medicine in women with diagnosed low sexual desire. It does not automatically apply to compounded sprays, other formulations or men.
Bremelanotide improved desire and reduced related distress compared with placebo.
1,267 premenopausal women randomized · Subcutaneous
What remains uncertain
Read the studyThe findings concern diagnosed HSDD in a defined population; adverse effects and label exclusions matter.
The early study reported an erectile response at studied doses.
Healthy men and men with erectile dysfunction · Intranasal
What remains uncertain
Read the studyThis was an early physiological study, not approval or validation of a compounded nasal-spray regimen.
About this evidence review
FDA approval concerns subcutaneous Vyleesi. It does not extend to a compounded nasal spray, another formulation, male use or UAE authorization.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss PT-141 Pen. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
How will my blood pressure, cardiovascular history and current medicines be reviewed?
03
Your follow-up
How will we review the plan?
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is PT-141 Pen considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
What should I know about the safety of PT-141 Pen?
Nausea, flushing and headache were reported. The approved label includes blood-pressure effects and contraindications in uncontrolled hypertension or known cardiovascular disease.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Bring your questions
Make your next step
a conversation.
Want to understand where PT-141 Pen fits? Discuss the evidence, your health history and the options with DarDoc.